logo-loader
Circassia Pharmaceuticals

Circassia's AirNOvent drug a step closer to market with FDA pre-submission meeting

Circassia Pharmaceuticals PLC (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott their partner, AIT Therapeutics Inc. has successfully completed a pre-submission meeting with the US FDA for the ventilator-compatible nitric oxide product AirNOvent.

AIT anticipates submitting a Premarket Approval application (PMA) for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN).

Circassia intends launching the product in the first half of 2020, once approved.

Quick facts: Circassia Pharmaceuticals

Price: £0.19

Market: LSE
Market Cap: £71.28 m
Follow

Watch

Circassia hires Pfizer exec as it continues transition to commerical business

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris caught up with Proactive London's Andrew Scott after news they've hired one of Pfizer’s top executives to become its first chief operating officer. Jonathan Emms, who has held a number of senior positions at both Pfizer and...

4 days, 3 hours ago

2 min read

;